Dr. Greta Josephine G. Miroy
Position: Associate Professor
Ph.D. Chemistry, Amyloid Disease Mechanism and Therapeutic Interventions Understanding
Texas A&M University; B.S. Chemistry, UP Diliman
Postdoctoral Fellow, Medical Biotechnology Center
University of Maryland Biotechnology Institute
Health and Well Being Biomarkers
Diagnostic Device Development
1. Inhibiting Transthyretin Amyloid Fibril Formation via Protein Stabilization. Miroy, GJ, Kelly, J.W. et al, Proceedings National Academy of Science. USA. Vol 93, pp15051.
2. Comparison of Lethal and Non-lethal Transthyretin Variants and their Relationship to Amyloid Disease. McCutchen, SL, Miroy, GM, Lai, Z, Kelly, JW, Colon , W. Biochemistry. Vol 34(41), pp13527.
3. Recombinant Human Retinol Binding Protein Refolding, Native Disulfide Formation and Characterization. Xie, Y, Lashuel, HA, Miroy, GJ, Dikler,S, Kelly, JW. Protein Expression and Purification.
4. Transthyretin Quarternary and Tertiary Structural Changes Facilitate Missassembly into Amyloid.Colon, W, Lai, Z, Miroy, G, McCulloch, J, McCutchen,S, LAshuel, H, Kelly, JW. Advances in Protein Chemistry, 50,pp161. Publication date: 10/8/1997
5. FAP Mutations Destabilize Transthyretin Facilitating Conformational Changes Required for Amyloid Formation’ in The Nature and Origin of Amyloid Fibrils. WileyChichester. Colon, W, Lai, Z, McCutchen, S, Miroy, G, Kelly JW.
6. Expression and purification of a convenient Ca-calmodulin dependent protein kinase II GST-fusion substrate. Miroy, GJ and Monteiro, M. Protein expression and Purification 2001:26(3) 343-8
7. Transthyretin quarternary and tertiary structural changes facilitate misassembly into amyloid by
Jeffery W. Kelly, Wilfredo Colon, Zhihong Lai, Hilala A. Lashuel, Jennifer McCulloch, Sandra L. Mccutchen, Greta J. Miroy and Scott Peterson 1997science direct 161-179